Tags

Type your tag names separated by a space and hit enter

Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease.

Abstract

OBJECTIVES

To compare the efficacy and safety of adjunct lisuride therapy versus bromocriptine in patients with Parkinson's disease, already established on levodopa and suffering the long-term complications of therapy.

SEARCH STRATEGY

Electronic searches of MEDLINE, EMBASE and the Cochrane Controlled Trials Register. Handsearching of the neurology literature as part of the Cochrane Movement Disorders Group's strategy. Examination of the reference lists of identified studies and other reviews. Contact with Cambridge Laboratories, Roche Products Limited and Sandoz Limited.

SELECTION CRITERIA

Randomised controlled trials of lisuride versus bromocriptine in patients with a clinical diagnosis of idiopathic Parkinson's disease and long-term complications of levodopa therapy.

DATA COLLECTION AND ANALYSIS

Data was abstracted independently by each author and differences settled by discussion.

MAIN RESULTS

Only one randomised cross-over trial including 20 patients has compared lisuride with bromocriptine as adjunct therapy in Parkinson's disease. Both lisuride and bromocriptine improved motor fluctuations with no significant differences between the agonists. However, this conclusion is based on an unvalidated 4 point rating scale which could only record positive outcomes. This, combined with the small size of the trial, suggests that firm conclusions on motor fluctuations should not be drawn. Lisuride and bromocriptine produced similar benefits in parkinsonian impairments according to the Columbia Rating Scale. Adverse events were similar with the two agonists and no withdrawals were reported from either drug.

REVIEWER'S CONCLUSIONS

The small size of this study and other methodological problems do not allow any firm conclusions to be drawn regarding the efficacy and safety of lisuride compared with bromocriptine in advanced Parkinson's disease with motor complications.

Authors+Show Affiliations

Department of Neurology, City Hospital NHS Trust, Dudley Road, Birmingham, West Midlands, United Kingdom, B18 7QH. c.e.clarke@bham.ac.ukNo affiliation info available

Pub Type(s)

Journal Article
Review
Systematic Review

Language

eng

PubMed ID

10796800

Citation

Clarke, C E., and J M. Speller. "Lisuride Versus Bromocriptine for Levodopa-induced Complications in Parkinson's Disease." The Cochrane Database of Systematic Reviews, 2000, p. CD001514.
Clarke CE, Speller JM. Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev. 2000.
Clarke, C. E., & Speller, J. M. (2000). Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease. The Cochrane Database of Systematic Reviews, (2), CD001514.
Clarke CE, Speller JM. Lisuride Versus Bromocriptine for Levodopa-induced Complications in Parkinson's Disease. Cochrane Database Syst Rev. 2000;(2)CD001514. PubMed PMID: 10796800.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Lisuride versus bromocriptine for levodopa-induced complications in Parkinson's disease. AU - Clarke,C E, AU - Speller,J M, PY - 2000/5/5/pubmed PY - 2000/7/8/medline PY - 2000/5/5/entrez SP - CD001514 EP - CD001514 JF - The Cochrane database of systematic reviews JO - Cochrane Database Syst Rev IS - 2 N2 - OBJECTIVES: To compare the efficacy and safety of adjunct lisuride therapy versus bromocriptine in patients with Parkinson's disease, already established on levodopa and suffering the long-term complications of therapy. SEARCH STRATEGY: Electronic searches of MEDLINE, EMBASE and the Cochrane Controlled Trials Register. Handsearching of the neurology literature as part of the Cochrane Movement Disorders Group's strategy. Examination of the reference lists of identified studies and other reviews. Contact with Cambridge Laboratories, Roche Products Limited and Sandoz Limited. SELECTION CRITERIA: Randomised controlled trials of lisuride versus bromocriptine in patients with a clinical diagnosis of idiopathic Parkinson's disease and long-term complications of levodopa therapy. DATA COLLECTION AND ANALYSIS: Data was abstracted independently by each author and differences settled by discussion. MAIN RESULTS: Only one randomised cross-over trial including 20 patients has compared lisuride with bromocriptine as adjunct therapy in Parkinson's disease. Both lisuride and bromocriptine improved motor fluctuations with no significant differences between the agonists. However, this conclusion is based on an unvalidated 4 point rating scale which could only record positive outcomes. This, combined with the small size of the trial, suggests that firm conclusions on motor fluctuations should not be drawn. Lisuride and bromocriptine produced similar benefits in parkinsonian impairments according to the Columbia Rating Scale. Adverse events were similar with the two agonists and no withdrawals were reported from either drug. REVIEWER'S CONCLUSIONS: The small size of this study and other methodological problems do not allow any firm conclusions to be drawn regarding the efficacy and safety of lisuride compared with bromocriptine in advanced Parkinson's disease with motor complications. SN - 1469-493X UR - https://www.unboundmedicine.com/medline/citation/10796800/Lisuride_versus_bromocriptine_for_levodopa_induced_complications_in_Parkinson's_disease_ L2 - https://doi.org/10.1002/14651858.CD001514 DB - PRIME DP - Unbound Medicine ER -